#Bioretec #Finland #Helsinki #RemeOs #Activa

Insights from Bioretec Ltd's Extraordinary General Meeting

On March 27, 2026, Bioretec Ltd held its Extraordinary General Meeting as a live virtual event in compliance with Finnish corporate regulations. This pivotal meeting approved crucial resolutions aimed at promoting the company's future growth, focusing on a potential rights offering and authorizing the issuance of shares and special rights.

Rights Offering Authorization

The meeting set forth an important resolution to empower the Board of Directors to conduct a rights offering. Up to a staggering 1.5 billion new shares may be issued, allowing existing shareholders to subscribe in proportion to their current holdings. The remaining unsold shares will be available for other investors, ensuring that the capital-raising process is equitable and transparent.

This offering, valid until June 30, 2026, represents a strategic move to bolster the company’s financial position, allowing for further investment in innovative medical technologies and sustained market growth. Over two-thirds of independent shareholders supported this resolution, reflecting robust confidence in Bioretec's strategic direction.

Share Issuance and Special Rights

In addition to the rights offering, the Board of Directors received authorization to issue up to 250 million shares or special rights to the shareholders. This flexibility is crucial for the financing of potential acquisitions, enhancing shareholder value, and funding innovative projects, particularly in the orthopedic sector where Bioretec operates.

It’s also noteworthy that the shares can either be newly created or treasury shares, illustrating the company’s preparedness to explore various funding mechanisms to support its growth strategy.

This authorization remains in effect until the company's annual meeting in 2027, granting Bioretec time to make well-considered decisions regarding its capital structure and strategic initiatives. The aim is for these share issuances to correspond to minimal dilution, targeting no more than a 12% dilution effect should a rights issue proceed.

Bioretec: An Industry Leader

As a frontrunner in medical devices focused on orthopedic care, Bioretec is renowned for its biodegradable implant solutions. Their cutting-edge product lines, including RemeOs™ and Activa, are grounded in advanced materials that promote natural healing processes, eliminating the need for secondary surgeries to remove implants.

RemeOs™ utilizes advanced magnesium alloys and hybrid composites, receiving significant market authorizations, including in the U.S. in March 2023 and in Europe in January 2025. This innovative approach aids in fracture healing, setting a new standard for orthopedic implants.

With a presence in around 40 countries, Bioretec's technology aims to enhance patient outcomes and redefine orthopedic treatment frameworks. Their commitment to developing effective medical solutions showcases the future direction of healthcare innovation.

Access to Meeting Minutes

For stakeholders seeking further details, the minutes from the Extraordinary General Meeting will be published on Bioretec's official website by April 10, 2026. This transparency underscores Bioretec’s commitment to open communication with its shareholders and the broader market.

Conclusion

Bioretec Ltd’s Extraordinary General Meeting revealed significant strategic intentions to reinforce its market position. With a clear focus on fostering innovation through rights offerings and share issuance, the company is poised for substantial growth in the evolving landscape of orthopedic care. Bioretec continues to shape the future of treatment technologies that align with patient needs and surgical advancements, solidifying its role as a leader in the industry.

To learn more about Bioretec’s groundbreaking developments, visit www.bioretec.com.